New Haven biotech firm cuts 45 percent of its workforce
Officials at Rallybio, which is developing drugs to treat rare diseases, said the job cuts will allow the company to continue operating through mid-2026. |!| New Haven
Officials at Rallybio, which is developing drugs to treat rare diseases, said the job cuts will allow the company to continue operating through mid-2026. |!| New Haven